Clinical Trials Logo

Abortion Early clinical trials

View clinical trials related to Abortion Early.

Filter by:

NCT ID: NCT05986357 Not yet recruiting - Abortion Early Clinical Trials

The Relation of High Sensitivity C Reactive Protein and Total Leucocytic Count Levels in Threatened Abortion

Start date: July 30, 2023
Phase:
Study type: Observational

to identify the relation between maternal serum high sensitivity C reactive protein and total and differential leucocytic count values in healthy pregnant women with threatened abortion and the outcome of pregnancy

NCT ID: NCT05781061 Recruiting - Abortion Early Clinical Trials

MA-ASAP at Independent Abortion Clinics: A Demonstration Project

Start date: February 16, 2023
Phase: N/A
Study type: Interventional

In this study, the investigators propose to conduct a parallel study to MA-ASAP (ClinicalTrials.gov Identifier: NCT05278780) at an independent clinic.

NCT ID: NCT05635955 Completed - Anesthesia Clinical Trials

Remimazolam Versus Propofol for Painless Abortion

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to compare the efficacy and safety of propofol vs. remimazolam in combine use of esketamine in women with early pregnancy undergoing painless abortion. The main questions it aims to answer are: - whether remimazolam plus esketamine (R+E) has a better sedative and analgesic effectiveness than propofol plus esketamine (P+E). - whether R+E has less adverse events than P+E. Participants will be randomly allocated to two groups: R+E and P+E group. - For those in group R+E: they will be administered with 0.3mg/kg remimazolam and 0.3mg/kg esketamine before the abortion surgery. - For those in group P+E: they will be administered with 2mg/kg propofol and 0.3mg/kg esketamine before the abortion surgery. We will compare R+E with P+E to see if the time to loss of conscious and time to recover from the sedation will be shorter and if there will be less severe adverse events in R+E.

NCT ID: NCT05342974 Active, not recruiting - Abortion Early Clinical Trials

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

Start date: April 19, 2022
Phase: Early Phase 1
Study type: Interventional

Medication abortion is a way of ending a pregnancy using pills. The current FDA-approved regimen for medication abortion uses mifepristone and misoprostol. This study is testing whether a different medication, atorvastatin, followed by misoprostol, can be used to end a pregnancy. Participants at 35-49 days of pregnancy will receive an oral dose of atorvastatin (80 mg) to swallow at the clinic as well as taking atorvastatin (80 mg) daily for six additional days, with a return to clinic on day 8 after initial visit to take a dose of misoprostol (800 mcg). Additionally, follow-up visits will occur on approximately days 3, 8 and 11 for a clinician to perform an ultrasound to see if the abortion is complete.

NCT ID: NCT05278780 Active, not recruiting - Abortion Early Clinical Trials

Medication Abortion With Autonomous Self-Assessment Project

MA-ASAP
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

In this study, the investigators propose to create and pilot-test an asynchronous medication abortion provision service.

NCT ID: NCT05182008 Recruiting - Clinical trials for Abortion in First Trimester

A Patient Decision Aid for Method of Early Abortion: A Randomized Control Trial

Start date: May 5, 2022
Phase: N/A
Study type: Interventional

Introduction: There are two options for women seeking early pregnancy termination in Canada; either surgical or medication abortion. When making a decision about which option is best for them, patient must consider their values as well as social resources and circumstances Patient decision aids (PtDAs) are tools to help patients make health-related decisions, particularly when no 'best' choice exist. Our research team has developed an online interactive patient decision aid on method of abortion based on international standards for decision aid development. We would like to investigate whether it leads to improved decisional quality in patients seeking early abortion. Methods: Phase 1 will be development of an abortion knowledge assessment tool. We will start by developing ten multiple choice questions based on information that is classically included in abortion education material. The goal is to ultimately include 5-7 well-performing questions in the trial. The ten questions will be sent to content experts to answer and rate. They will rate the questions on representativeness and importance. The questions will also be administered to community members without specific abortion knowledge. Results will be used to assess content validity and discriminator validity and revise the questionnaire. Phase 2 will be a randomized trial of people seeking abortion at less than 63 days gestation. Those who wish to participate will be randomized either the decision aid (study group) or the standard abortion clinic website (control). They will then be asked to participate in a survey immediately after they are finished reviewing the decision aid or website to. This survey will include questions about their decision, demographics, medical history, and their level of knowledge about abortion methods (by administering the knowledge assessment tool described above). The evaluation of the decision making will be measured using the Decisional Conflict Score. Four weeks post procedure, participants will be contacted by e-mail again and asked to complete a second survey identifying which type of abortion they underwent along with an inventory of perceived adverse treatment effects, as well as completing a Satisfaction with Decision Scale (SWD)

NCT ID: NCT05147857 Recruiting - Abortion Early Clinical Trials

Mid Trimester Abortion Effectiveness by Dilapan s

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study is done aiming to find out an effective method to induce second trimester abortion within a reasonable time and with the least possible cost and complications.

NCT ID: NCT04824118 Completed - Clinical trials for Venous Thromboembolism

Clotting Parameters After Medical Abortion

C-PLAN
Start date: March 26, 2021
Phase:
Study type: Observational

Venous thromboembolism (VTE - blood clots that form in deep veins or in the lungs) has been identified as a leading cause of death in economically developed countries for pregnant and recently-pregnant women. There is evidence that clotting parameters can take up to 6 weeks to return to normal for women who have had term deliveries, however there is an absence of information on time taken for clotting parameters to normalise following abortion. As such, existing guidelines are based solely on expert opinion and recommend durations of VTE prevention from as short as 7 days, up to 6 weeks following abortion. All women are assessed for risk of VTE, but data are needed to inform an evidence-based approach to prevention of VTE in these women. The findings from this pilot study have the potential to inform clinical guidance and possibly a larger study subsequently.

NCT ID: NCT04458558 Recruiting - Pregnancy Related Clinical Trials

Improving Access to Abortion in the Republic of Georgia

Start date: June 30, 2020
Phase: Phase 4
Study type: Interventional

In the Republic of Georgia, the medical abortion regimen involves three in-person visits. This study aims to pilot and evaluate a simplified medical abortion service delivery model that will reduce the number of in-person visits to only one visit for diagnosis and counseling. Medication will be mailed along with two multi-level pregnancy tests to study participants, who will assess their abortion outcome at home.

NCT ID: NCT04432792 Completed - Abortion Early Clinical Trials

The California Home Abortion by Telehealth (CHAT) Study

CHAT
Start date: May 1, 2021
Phase:
Study type: Observational

This study aims to assess efficacy and safety outcomes of a telehealth model of abortion care. The study will compare efficacy of this model to usual in-clinic care based on published rates. It will also investigate participant acceptability and feasibility of this model of care.